Survival Benefit With Adjuvant Chemotherapy Based on Molecular Residual Disease in Patients With Resected Colorectal Liver Metastases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: subgroup analysis from CIRCULATE-Japan GALAXY
Ann. Oncol 2024 Sep 16;[EPub Ahead of Print], K Kataoka, K Mori, Y Nakamura, J Watanabe, N Akazawa, K Hirata, M Yokota, K Kato, M Kotaka, K Yamazaki, Y Kagawa, S Mishima, K Ando, M Miyo, H Yukami, G Laliotis, S Sharma, CC Palsuledesai, M Rabinowitz, A Jurdi, MC Liu, A Aleshin, D Kotani, H Bando, H Taniguchi, I Takemasa, T Kato, T Yoshino, E OkiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.